Human Genome Sciences (NASDAQ:HGSI)

CAPS Rating: 2 out of 5

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Recs

0
Player Avatar modestus1 (< 20) Submitted: 10/23/2011 12:57:58 AM : Outperform Start Price: $13.24 HGSI Score: -3.59

Buy the rumor, sell the news.

Featured Broker Partners


Advertisement